Skip to main
ELAN
ELAN logo

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health demonstrates a robust market position, with Simparica Trio leading the market with over 50% share, and Credelio Quattro projected to increase its market share to 16.8% by 2026, indicating positive growth potential in its product offerings. Additionally, the Advantage Family and Seresto products have shown impressive year-over-year growth of 33% and 28%, respectively, in the third quarter of 2025, reinforcing the company’s strong sales momentum. These indications of market leadership and consistent product performance contribute to a favorable outlook for Elanco Animal Health's stock.

Bears say

Elanco Animal Health faces potential refinancing risks that could adversely impact earnings growth in 2026, particularly in light of comparable companies pricing high-yield offerings, such as Dentsply Sirona’s recent $550 million issuance at 8.375%. Additionally, while Elanco's revenue has increased by approximately 50%, the EBITDA margin has decreased by a couple of hundred basis points, indicating challenges in maintaining profitability amidst rising sales. Although the company reported a $28 million EBITDA outperformance in the second quarter, the broader trend of margin compression raises concerns about sustainable financial health.

ELAN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 8 analysts, ELAN has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.